All text is © British Library Board and is available under a Creative Commons Attribution Licence, except where otherwise stated.
Explore the British Library
7 results for Everything in this catalogue
Sort by:
Sort by:
relevanceOr hit Enter to replace sort method
- relevance
- date-newest
- date-oldest
- Title
- Author
| Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
|---|---|---|---|
| 1 |
Material Type: Article
|
|
Management of toxicities of immune checkpoint inhibitorsSpain, Lavinia; Diem, Stefan; Larkin, JamesCancer treatment reviews. Volume 44 (2016); pp 51-60 -- ElsevierOnline access |
| 2 |
Material Type: Article
|
|
Prognostic score for patients with advanced melanoma treated with ipilimumabDiem, Stefan et al.European journal of cancer. Volume 51:Issue 18 (2015, December); pp 2785-2791 -- ElsevierOnline access |
| 3 |
Material Type: Article
|
|
Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumabDiem, Stefan et al.Lung cancer. Volume 111 (2017); pp 176-181 -- Elsevier Science Pub. CoOnline access |
| 4 |
Material Type: Article
|
|
Pembrolizumab-triggered Uveitis: An Additional Surrogate Marker for Responders in Melanoma Immunotherapy?Diem, Stefan et al.Journal of immunotherapy: official journal of the Society for Biological Therapy. Volume 39:Issue 9 (2016, November/December) -- Lippincott Williams & WilkinsOnline access |
| 5 |
Material Type: Article
|
|
Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitorsHasan Ali, Omar et al.European journal of cancer. Volume 107 (2019); pp 8-14 -- ElsevierOnline access |
| 6 |
Material Type: Article
|
|
Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitorsHasan Ali, Omar et al.European journal of cancer. Volume 107: (2019, January); pp 8-14 -- ElsevierOnline access |
| 7 |
Material Type: Article
|
|
Immunoglobulin G and Subclasses as Potential Biomarkers in Metastatic Melanoma Patients Starting Checkpoint Inhibitor TreatmentDiem, Stefan et al.Journal of immunotherapy: official journal of the Society for Biological Therapy. Volume 42:Issue 3 (2019, April); pp 89-93 -- Lippincott Williams & WilkinsOnline access |
Refine Search Results
Author/Contributor
- Flatz, Lukas (5)
- Fässler, Mirjam (3)
- Berner, Fiamma (3)
- Früh, Martin (3)
- Bomze, David (3)
- Hasan Ali, Omar (2)
- Cozzio, Antonio (2)
- Driessen, Christoph (2)
- Dummer, Reinhard (2)
- Jörger, Markus (2)
- Larkin, James (2)
- Lenz, Tobias L. (2)
- Gore, Martin (1)
- Rüesch, Reinhard (1)
- Goldinger, Simone M. (1)
- Krapf, Mirjam (1)
- Born, Diana (1)
- Urner-Bloch, Ursula (1)
- Keller, Fabienne (1)
-
Refine further
Subject
- Periodicals (5)
- Cancer--Périodiques (4)
- Cancer--Periodicals (4)
- Neoplasms--Periodicals (3)
- Neoplasms--therapy--Periodicals (3)
- Tumors (3)
- Cancer (3)
- Immunotherapy--Periodicals (2)
- Cancer immunotherapy--Immune-related adverse events--Human leukocyte antigen--Therapeutic marker--Non (2)
- melanoma--immunotherapy--uveitis (1)
- immunoglobulins--subclasses--metastatic melanoma--checkpoint inhibitor--biomarker--response (1)
- Cancer--Treatment (1)
- Lungs--Cancer (1)
- Lung Neoplasms--Periodicals (1)
- Cancer--Treatment--Periodicals (1)
- Lungs--Cancer--Periodicals (1)
- Non small cell lung cancer--Immunotherapy--Neutrophil-to-Lymphocyte ratio--Platelet-to-Lymphocyte ratio--Overall survival (1)
- Poumons--Cancer--Périodiques (1)
- Cancer--Traitement--Périodiques (1)
- Immune-checkpoint inhibitors--Immune-related adverse events--Ipilimumab--Nivolumab--Pembrolizumab--Melanoma--Lung cancer--Renal cancer (1)
-
Refine further